ATLANTA — The American Society of Hematology’s annual meeting here has been buzzing about CAR-T therapies. New data show the treatment’s effects can be quite durable — at least for some patients — and suggest that it might be safe to administer some CAR-Ts on an outpatient basis.
For some insight into the early rollout of one of the first CAR-Ts to hit the market, STAT sat down for a quick interview with Dr. David Chang, the chief medical officer of Kite, now a part of Gilead Sciences (GILD).
About the Author Reprints
Adam check out IMUC press release!
Huge News!